EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A-series agent A-234: initial in vitro and in vivo characterization

Martina Hrabinova, Jaroslav Pejchal, Vendula Hepnarova iD, Lubica Muckova, Lucie Junova, Jakub Opravil, Jana Zdarova Karasova, Tomas Rozsypal, Alzbeta Dlabkova, Helena Rehulkova, Tomas Kucera, Zbyněk Vecera und 4 weitere

Archives of Toxicology · 2024

DOI: 10.1007/s00204-024-03689-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Toxicology, 2024. Verfasst von Martina Hrabinova und 15 weiteren Autor:innen. Beteiligte Einrichtung: University of Defence, Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, Trebesska 1575, 500 01, Hradec Králové, Czech Re…. Hauptthemen laut MEDLINE: Cholinesterase Reactivators, Pralidoxime Compounds. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Defence.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A-series agent A-234 belongs to a new generation of nerve agents. The poisoning of a former Russian spy Sergei Skripal and his daughter in Salisbury, England, in March 2018 led to the inclusion of A-234 and other A-series agents into the Chemical Weapons Convention. Even though five years have already passed, there is still very little information on its chemical properties, biological activities, and treatment options with established antidotes. In this article, we first assessed A-234 stability in neutral pH for subsequent experiments. Then, we determined its inhibitory potential towards human recombinant acetylcholinesterase ( Hss AChE; EC 3.1.1.7) and butyrylcholinesterase ( Hss BChE; EC 3.1.1.8), the ability of HI-6, obidoxime, pralidoxime, methoxime, and trimedoxime to reactivate inhibited cholinesterases (ChEs), its toxicity in rats and therapeutic effects of different antidotal approaches. Finally, we utilized molecular dynamics to explain our findings. The results of spontaneous A-234 hydrolysis showed a slow process with a reaction rate displaying a triphasic course during the first 72 h (the residual concentration 86.2%). A-234 was found to be a potent inhibitor of both human ChEs ( Hss AChE IC 50 = 0.101 ± 0.003 µM and Hss BChE IC 50 = 0.036 ± 0.002 µM), whereas the five marketed oximes have negligible reactivation ability toward A-234-inhibited Hss AChE and Hss BChE. The acute toxicity of A-234 is comparable to that of VX and in the context of therapy, atropine and diazepam effectively mitigate A-234 lethality. Even though oxime administration may induce minor improvements, selected oximes (HI-6 and methoxime) do not reactivate ChEs in vivo. Molecular dynamics implies that all marketed oximes are weak nucleophiles, which may explain the failure to reactivate the A-234 phosphorus-serine oxygen bond characterized by low partial charge, in particular, HI-6 and trimedoxime oxime oxygen may not be able to effectively approach the A-234 phosphorus, while pralidoxime displayed low interaction energy. This study is the first to provide essential experimental preclinical data on the A-234 compound.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholinesterase ReactivatorsPralidoxime CompoundsRatsHumansAnimalsTrimedoximeButyrylcholinesteraseAcetylcholinesteraseOximesPyridinium CompoundsAntidotesCholinesterase InhibitorsPhosphorusOxygenTaurine

Stichwörter der Autor:innen

Acute toxicityHydrolysisNerve agent A-234ReactivationTherapy

Substanzen

asoxime chlorideN,N'-monomethylenebis(pyridiniumaldoxime)pralidoximeCholinesterase ReactivatorsTrimedoximeButyrylcholinesteraseAcetylcholinesterase2-(N-cyclohexylamino)ethanesulfonic acidOximesPyridinium Compounds

Autor:innen und Institutionen

  • University of Defence, Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, Trebesska 1575, 500 01, Hradec Králové, Czech Republic.
  • University of Defence, Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, Trebesska 1575, 500 01, Hradec Králové, Czech Republic. vendula.hepnarova@unob.cz.
  • University Hospital Hradec Kralove, Biomedical Research Centre, Sokolska 581, 500 05, Hradec Králové, Czech Republic.
  • University of Defence, Nuclear, Biological, and Chemical Defence Institute, Vita Nejedleho 1, 68203, Vyskov, Czech Republic.
  • University of Defence, Military Faculty of Medicine, Department of Military Medical Service Organization and Management, Trebesska 1575, 500 01, Hradec Králové, Czech Republic.
  • University Hospital Hradec Kralove, Department of Neurology, Sokolska 581, 500 05, Hradec Králové, Czech Republic.

ORCID-Profile: Vendula Hepnarova, Daniel Jun

Förderung

  • University of Defence

Zitieren

APA

Hrabinova, M., Pejchal, J., Hepnarova, V., Muckova, L., Junova, L., Opravil, J., Zdarova Karasova, J., Rozsypal, T., Dlabkova, A., Rehulkova, H., Kucera, T., Vecera, Z., Caisberger, F., Schmidt, M., Soukup, O., & Jun, D. (2024). A-series agent A-234: initial in vitro and in vivo characterization. Archives of Toxicology. https://doi.org/10.1007/s00204-024-03689-3

Vancouver

Hrabinova M, Pejchal J, Hepnarova V, Muckova L, Junova L, Opravil J, et al. A-series agent A-234: initial in vitro and in vivo characterization. Archives of Toxicology. 2024. doi:10.1007/s00204-024-03689-3

BibTeX
@article{Hrabinova2024,
  author = {Hrabinova, Martina and Pejchal, Jaroslav and Hepnarova, Vendula and Muckova, Lubica and Junova, Lucie and Opravil, Jakub and Zdarova Karasova, Jana and Rozsypal, Tomas and Dlabkova, Alzbeta and Rehulkova, Helena and Kucera, Tomas and Vecera, Zbyněk and Caisberger, Filip and Schmidt, Monika and Soukup, Ondrej and Jun, Daniel},
  title = {A-series agent A-234: initial in vitro and in vivo characterization},
  journal = {Archives of Toxicology},
  year = {2024},
  doi = {10.1007/s00204-024-03689-3}
}
Kostenlos starten →